Seres Therapeutics (NASDAQ:MCRB) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Seres Therapeutics (NASDAQ:MCRB) to a hold rating in a research note published on Tuesday,Zacks.com reports.

Several other research firms have also weighed in on MCRB. Wall Street Zen raised Seres Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. HC Wainwright initiated coverage on shares of Seres Therapeutics in a report on Tuesday. They issued a “buy” rating and a $12.00 target price for the company. Canaccord Genuity Group restated a “buy” rating and issued a $22.00 price target on shares of Seres Therapeutics in a research note on Friday, March 13th. Finally, Weiss Ratings lowered shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $17.00.

Seres Therapeutics Price Performance

Shares of MCRB opened at $6.83 on Tuesday. The firm has a 50 day simple moving average of $7.43 and a two-hundred day simple moving average of $10.59. Seres Therapeutics has a one year low of $5.31 and a one year high of $29.98. The company has a market cap of $66.07 million, a P/E ratio of -1.32 and a beta of 0.13.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.88) by ($0.20). The business had revenue of $0.36 million during the quarter, compared to analysts’ expectations of $0.36 million. On average, analysts expect that Seres Therapeutics will post -5.84 earnings per share for the current fiscal year.

Institutional Trading of Seres Therapeutics

A number of hedge funds have recently made changes to their positions in MCRB. Marshall Wace LLP acquired a new stake in Seres Therapeutics in the second quarter valued at $1,016,000. Invesco Ltd. grew its position in shares of Seres Therapeutics by 193.2% in the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 89,995 shares during the last quarter. 683 Capital Management LLC acquired a new stake in shares of Seres Therapeutics in the fourth quarter valued at about $778,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Seres Therapeutics in the third quarter valued at about $557,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 21,679 shares during the last quarter. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical?stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.